Kyowa Kirin Co.,Ltd. (4151) Stock Price

Kyowa Kirin is primarily engaged in the manufacturing and sales of prescription pharmaceuticals. The company is a subsidiary of Kirin Holdings Company, Limited, and operates as the parent company of a group that includes 43 subsidiaries and 14 associates accounted for using the equity method. This group conducts business related to pharmaceutical products.

Kyowa Kirin's operations are specialized in the manufacturing and sales of prescription pharmaceuticals. Specific products and services are detailed in the company overview and information on related companies. By conducting integrated operations from drug development through sales, the company contributes to healthcare delivery.

Additionally, Kyowa Kirin previously conducted business operations in the Asia-Pacific region. However, Kyowa Kirin Asia Pacific Pte. Ltd. and Kyowa Kirin Hong Kong Limited were scheduled for dissolution and liquidation effective August 1, 2024. This reflects an ongoing review of the company's regional strategy.

Kyowa Kirin's management philosophy is to pursue advances in life sciences and technology, and contribute to the health and prosperity of people worldwide through the creation of new value. In its vision toward 2030, the company aims to establish itself as a Japan-based global specialty pharmaceutical company that brings smiles to people facing disease.

The company practices CSV (Creating Shared Value) management to achieve both social and economic value, with the goal of enhancing corporate value. Based on the shared corporate value "Commitment to Life," the company strives to remain a trusted enterprise.

Kyowa Kirin has identified key management priorities for realizing its 2030 vision and is advancing strategies based on "Story for Vision 2030." The company is particularly focused on the areas of "bone and mineral disorders," "blood cancers and intractable hematologic diseases," and "rare diseases," while accelerating drug discovery by integrating technology and expertise.

On the technology front, the company is building platforms based on innovative modalities, utilizing advanced antibody technology and hematopoietic stem cell gene therapy technology. The company is further strengthening open innovation and partner collaborations to maximize value creation.

Kyowa Kirin is expanding the market for products such as Crysvita and Poteligeo, and aims to provide new treatment options for acute leukemia. The company is also advancing development of antibody-drug conjugates and gene therapies to accelerate value delivery to patients.

As a strategic partnering asset, the company is advancing multiple clinical trials through collaboration with Amgen. The company is also developing products utilizing proprietary technology and maximizing value through cooperation with partners.